GH Research Announces Publication of Phase 2b Results for Depression Treatment GH001

Key Facts

1GH Research announced the publication of Phase 2b results for GH001 in JAMA Psychiatry.

2A new analysis demonstrated that the drug's efficacy is independent of the number of prior treatment failures.

3GH001 (Mebufotenin) targets patients with treatment-resistant depression (TRD).

GH Research PLC (Nasdaq: GHRS) announced the publication of Phase 2b clinical trial results for its lead candidate, GH001, in the prestigious journal JAMA Psychiatry. The study focuses on GH001 (Mebufotenin), a treatment designed for patients suffering from treatment-resistant depression (TRD). A significant new analysis revealed that the drug's efficacy remains consistent regardless of the number of prior treatment failures a patient has experienced. This finding suggests that GH001 could serve a broader range of patients within the TRD population, significantly enhancing its market potential. The peer-reviewed publication provides critical clinical validation for the company's therapeutic approach and its potential to change psychiatric practice. Investors view this development as a positive step toward the future regulatory and commercial success of GH Research.